Graham Packham

Emeritus Professor Graham Packham is affiliated with the University of Southampton, focusing on haematological malignancies, particularly B-cell receptor (BCR) signaling in chronic lymphocytic leukemia (CLL) and lymphomas. His research spans cancer biology, epigenetics, and drug development, with collaborations on targeted therapies and translational research. Key sponsors include Cancer Research UK, Blood Cancer UK, and industry partners like Aquinox Pharmaceuticals. He leads and contributes to multiple projects investigating therapeutic strategies for B-cell malignancies, autophagy regulation, and resistance mechanisms.

Notable projects include exploring BET inhibitors in lymphomas, developing PROTAC technology, and evaluating SHIP1 activators against B-cell cancers. Packham’s work emphasizes translational applications, such as personalized epigenetic therapies for follicular lymphoma and preclinical drug testing. He collaborates with institutions like Queen Mary University of London and Gilead Sciences, addressing challenges in CLL treatment and drug resistance.

His contributions extend to understanding BCR signaling pathways and their interplay with NOTCH1 in leukemia, as well as the role of environmental factors like particulate matter in cellular stress responses. Grants and partnerships highlight his role in advancing clinical and preclinical research in oncology and haematology.